Back to results
US 2014/0370043 A1Published application
Vesicular stomatitis virus for prime boost vaccine
AssigneeThe University of Western Ontario
InventorsChil-Yong Kang, Gyoung Nyoun Kim
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe University of Western Ontario
InventorsChil-Yong Kang, Gyoung Nyoun Kim
Estimating the term…
The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to a phenylalanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position (22), a leucine changed to a phenylalanine at position (110) and a methionine changed to an arginine at positions (48) and (51). The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher.
A modified matrix (M) protein of a vesicular stomatitis virus (VSV), characterized in that the modified M protein comprises an amino acid sequence selected from the group consisting of (i) SEQ ID NO:
A recombinant VSV (rVSV), characterized in that said rVSV comprises a modified matrix (M) protein, the modified M protein comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO:
A vaccine, characterized in that the vaccine comprises an effective amount of one or more attenuated rVSVs, the one or more attenuated rVSVs including a modified matrix (M) protein, the modified M protein comprising an amino acid sequence selected from the group consisting of:
The vaccine according to claim 33, characterized in that the lentivirus is a HIV and the epitope is a HIV protein.
A method of inducing an immune response in a subject, characterized in that the method comprises administering to the subject:
A prime boost combination vaccine, characterized in that the prime boost combination vaccine comprises:
A kit comprising:
An isolated peptide comprising an amino acid sequence selected from the group of amino acid sequences listed as SEQ ID NOs:
Dependencies are inferred from the claim text.